title: Comparison of outcomes after transplantation of peripheral blood stem cells versus bone marrow following an identical nonmyeloablative conditioning regimen.
abstract: This is the first study to examine the outcomes in 54 patients with hematologic malignancies who received an HLA-matched related donor bone marrow (BM, n = 42) or GCSF-mobilized peripheral blood stem cells (PBSC, n = 12) following identical nonmyeloablative conditioning with the intention of induction of mixed chimerism (MC) followed by prophylactic donor leukocyte infusion (pDLI) to convert MC to full donor chimerism (FDC) and capture a graft-versus-tumor effect without clinical graft-versus-host disease (GVHD). Neutrophil and platelet recovery were faster and transfusion requirement was less in PBSC recipients (P < 0.05). A total of 48% of BMT recipients achieved FDC with a median conversion time of 84 days, including 13 following pDLI. In contrast, 83% (P = 0.04) in the PBSC group had spontaneous FDC at a median of 14 days, precluding the administration of pDLI. There was no significant difference in the incidences of acute or chronic GVHD, though the rates of chronic GVHD were considerably higher in PBSC group than in the BM group (6/7, 86% vs 10/24, 42%). CD4 and CD8 T-cell recovery was faster in PBSC recipients. In PBSC recipients, a higher number of CD34+ cells was associated with increased rates of severe, grade III-IV acute GVHD.
authors.affiliation: Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA.
authors.forename: B R
authors.initials: BR
authors.lastname: Dey
authors.forename: J
authors.initials: J
authors.lastname: Shaffer
authors.forename: A J
authors.initials: AJ
authors.lastname: Yee
authors.forename: S
authors.initials: S
authors.lastname: McAfee
authors.forename: M
authors.initials: M
authors.lastname: Caron
authors.forename: K
authors.initials: K
authors.lastname: Power
authors.forename: D T
authors.initials: DT
authors.lastname: Ting
authors.forename: C
authors.initials: C
authors.lastname: Colby
authors.forename: F
authors.initials: F
authors.lastname: Preffer
authors.forename: K
authors.initials: K
authors.lastname: Ballen
authors.forename: E
authors.initials: E
authors.lastname: Attar
authors.forename: S
authors.initials: S
authors.lastname: Saidman
authors.forename: N
authors.initials: N
authors.lastname: Tarbell
authors.forename: D
authors.initials: D
authors.lastname: Sachs
authors.forename: M
authors.initials: M
authors.lastname: Sykes
authors.forename: T R
authors.initials: TR
authors.lastname: Spitzer
mesh_terms: D000328:Adult; D016026:Bone Marrow Transplantation; D005190:Family; D005260:Female; D016179:Granulocyte Colony-Stimulating Factor / Q000627:therapeutic use; D019337:Hematologic Neoplasms / Q000628:therapy*; D019650:Hematopoietic Stem Cell Mobilization / Q000379:methods; D006650:Histocompatibility Testing; D006801:Humans; D008297:Male; D008875:Middle Aged; D012008:Recurrence; D033581:Stem Cell Transplantation; D018183:Transplantation Chimera; D019172:Transplantation Conditioning / Q000379:methods*; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome
chemical_list: D016179:Granulocyte Colony-Stimulating Factor